RETRACTED: Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer
International Journal of Cancer · 01.09.2026 · 159 (5)
DOI: 10.1002/ijc.70163 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift International Journal of Cancer, online erschienen am 16.09.2025. Verfasst von Leandro Rodrigues Santiago und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Cancer Research (ICR), Genomics Facility, London, UK. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
Polygenic risk scores (PRS) and the prostate specific antigen (PSA) test have been shown to be successful tools for predicting prostate cancer (PCa) incidence. In this study, we assessed the potential of combining PRS and PSA as biomarkers for PCa aggressiveness and subsequent mortality from patients with low to intermediate risk PCa from the TAPG‐TURP cohort. Targeted sequencing of 140 PCa‐related genes was performed using 162 prostate samples from PCa patients with a Gleason score of 6 or 7, 80 of whom died from the disease. An additional 305 genome samples from healthy participants of the 1000 Genomes Project phase 3 were selected as controls. Two novel PRSs were developed using 21 single nucleotide polymorphisms (SNPs) selected from those differentiated between alive ( n = 82) and dead ( n = 80) PCa patients. The first PRS was used in decision tree‐based models, such as random forest (rf) able to accurately distinguish cancer from healthy samples (sensitivity = 100%, specificity = 100%, AUC = 1). The second PRS was used together with Gleason score and PSA in an artificial neural network model able to determine the aggressiveness of PCa by predicting PCa mortality with intermediate to high accuracy (sensitivity = 90%, specificity = 68.8%, AUC = 0.718). Further work must be done using our two machine learning classifiers to validate them further and apply them in the clinic, bypassing the necessity of invasive and more expensive approaches. Their application will potentially guide the clinical decision‐making process and reduce costs of the clinical management of PCa patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Institute of Cancer Research (ICR), Genomics Facility, London, UK.
- Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
- Institute of Opthalmology, University College London, London, UK.
ORCID-Profile: Belinda Nedjai
Förderung
- Cancer Research UK
Zitieren
APA
Santiago, L. R., Ladoukakis, E., Scibior-Bentkowska, D., & Nedjai, B. (2026). RETRACTED: Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer. International Journal of Cancer, 159(5). https://doi.org/10.1002/ijc.70163
Vancouver
Santiago LR, Ladoukakis E, Scibior-Bentkowska D, Nedjai B. RETRACTED: Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer. International Journal of Cancer. 2026;159(5). doi:10.1002/ijc.70163
BibTeX
@article{Santiago2026,
author = {Santiago, Leandro Rodrigues and Ladoukakis, Efthymios and Scibior-Bentkowska, Dorota and Nedjai, Belinda},
title = {RETRACTED: Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {5},
doi = {10.1002/ijc.70163}
}
EUVIMED